Secretory IgA (sIgA) is the primary mucosal antibody coating gut epithelium and luminal contents, exported as a secretory component–IgA complex after local production in lamina propria plasma cells. Some consumer gut panels measure stool sIgA and frame it as “immune strength,” “barrier support,” or “leaky gut risk.” Stool sIgA reflects antigen exposure and mucosal immune activity in the sampled stool, not a complete picture of systemic immunity or intestinal permeability.
Assay standardization across wellness labs is limited. Interpretation should stay context-specific and symptom-linked, not supplement-driven from a single value.
sIgA vs barrier vs calprotectin
These markers answer different questions and should not be merged on a report narrative:
| Marker | What it reflects | Typical clinical use | On wellness panels |
|---|---|---|---|
| Stool sIgA | Mucosal antibody export into lumen | Research; selected specialist contexts | ”Immunity score”, variable validation |
| Fecal calprotectin | Neutrophil protein in stool | IBD monitoring, inflammatory diarrhoea workup | Occasionally bundled, see Calprotectin |
| Permeability tests | Small molecule absorption (e.g. lactulose/mannitol, research/clinic) | Coeliac, IBD research protocols | Not measured by sIgA |
| Zonulin (stool/serum) | Claimed tight-junction proxy | Contested ELISA validity | See Zonulin |
High sIgA in research can follow acute infection, allergic or food-antigen challenge, or inflammatory states, it is not automatically protective. Low sIgA in stool may appear with hypogammaglobulinaemia in clinical immunology, but consumer panels do not substitute for serum immunoglobulin workup when recurrent infections occur.
For barrier framing without overclaim: Intestinal barrier. For inflammation tiering: Gut inflammation markers. Mucosal immunity hub: Gut–immune axis.
Clinical uses vs wellness panels
In hospital and research settings, mucosal IgA is studied in coeliac disease, IBD, IgA deficiency, and infectious enteritis. Clinical pathways use serum IgA, endoscopy, calprotectin, and histology, not isolated stool sIgA from a home kit.
Wellness panels often imply:
| Marketing claim | Evidence reality |
|---|---|
| ”Low sIgA = leaky gut” | Permeability requires different assays; barrier biology is not one antibody readout |
| ”Raise sIgA with probiotics” | Strain-specific, endpoint-specific trials; not generalizable from abundance marketing |
| ”High sIgA = strong immunity” | May indicate active antigenic load or inflammation |
| ”Optimal range” on report | Vendor reference band, rarely guideline-backed |
If you have recurrent sinopulmonary infections, chronic diarrhoea with weight loss, or known celiac/IBD, standard clinical immunology and gastroenterology workup precedes interpretation of a wellness sIgA line.
What affects stool sIgA on a single sample
| Factor | Effect |
|---|---|
| Recent GI infection | Transient rise common |
| Dietary antigen exposure | Variable sIgA responses in challenge studies |
| Sample handling and freeze-thaw | Proteolysis lowers apparent sIgA |
| Diurnal and day-to-day variation | Limited consumer reference intervals |
| Blood in stool | Confounds interpretation |
| Medications (PPIs, immunosuppressants) | Alters mucosal immune milieu |
Without repeat sampling and stable context, a one-off low or high value is weak evidence for any intervention.
High vs low on reports
| Report flag | Plausible contexts | Weak conclusions |
|---|---|---|
| High sIgA | Recent infection, antigen exposure, some inflammatory states | Must take binders or antimicrobials |
| Low sIgA | Hypogammaglobulinaemia (clinical), assay artefact, variable secretion | ”Leaky gut” proven; need generic probiotic |
| In-range | Within vendor cohort | Mucosal health guaranteed |
Pair sIgA with symptoms, calprotectin (if available), and clinical history, not with dysbiosis scores alone (Multi-marker synthesis).
What not to conclude from stool sIgA
| If the report says… | Do not conclude… |
|---|---|
| Low sIgA | You have common variable immunodeficiency without serum Ig workup |
| High sIgA | You have active IBD (use calprotectin and clinic assessment) |
| Below optimal range | You need colostrum, glutamine, or immune supplements |
| Normal sIgA | Intestinal barrier is intact |
| sIgA changed on retest | Immune improvement without symptom and assay control data |
Related pages
- Reading your microbiome report, hub for report lines
- Intestinal barrier, permeability vs composition
- Gut inflammation markers, calprotectin tier
- Calprotectin, validated inflammatory marker
- Zonulin, contested barrier proxy
- Red flags, when to seek care